Comparison of Atorvastatin and Rosuvastatin in Reduction of Inflammatory Biomarkers in Patients with Acute Coronary Syndrome

Kumar, Besham; Shah, Mir Ali; Kumar, Rajesh; Kumar, Jai; Memon, Aurangzeb

doi:10.7759/cureus.4898

Cited by 8 publications

(11 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This may be because our research period is too short. In other studies, the effect of decreasing hs-CRP of the statins was evident after 4 weeks, 6 weeks, and 12 weeks of treatment 15,25 .…”

Section: Discussionmentioning

confidence: 69%

See 1 more Smart Citation

Efficacy of Rosuvastatin and Atorvastatin in Vietnamese Patients with Acute Coronary Syndrome: A randomized trial

Tran¹,

Nguyen²,

Tran³

et al. 2021

Pharm Sci Asia

View full text Add to dashboard Cite

High-intensity statins have been recommended to initiate in patients after acute coronary syndrome (ACS) to reduce the risk of death and recurrent cardiovascular events. There have been few studies comparing the effectiveness of high-intensity statins in Vietnam. Therefore, we conducted a randomized controlled trial to compare the effects of rosuvastatin versus atorvastatin in Vietnamese patients with ACS. A total of 96 ACS patients were randomized into 2 groups at a ratio of 1:1 to receive rosuvastatin 20 mg/day or atorvastatin 40 mg/day in addition to the standard treatment of ACS. LDL-c and hs-CRP levels were measured before and after the intervention for analysis. No significant differences were found between the two groups at baseline. LDL-c levels were significantly reduced from baseline to 4-day in both groups (p<0.001 in both groups), but the difference in LDL-c levels at 4-day between the groups was not statistically significant (p=0.251). hs-CRP did not increase significantly in the rosuvastatin group but significantly in the atorvastatin group (p=0.209 and p<0.001, respectively). hs-CRP at 4-day was not significantly different between the two groups (p=0.250). The proportion of LDL <1.8 mmol/L after 4 days in the rosuvastatin group was significantly higher than that of the atorvastatin group (OR=4.592; 95% CI 1.365-15.449; p=0.014). There was no significant difference in the LDL-c reduction ≥50% and hs-CRP ≤3 mg/L at 4-day between two groups. In conclusion, rosuvastatin is more effective than atorvastatin in achieving LDL-c targets of <1.8 mmol/L after 4 days in Vietnamese patients with ACS.

show abstract

Section: Discussionmentioning

confidence: 69%

“…In recent years, several studies have been done to compare the effects of high-intensity statins in patients after ACS around the world. Rosuvastatin seems to be more effective than atorvastatin in reducing LDL-c and hs-CRP levels 15,16 . However, very few clinical trials have been conducted in Vietnam to discuss this issue.…”

Section: Introductionmentioning

confidence: 98%

Efficacy of Rosuvastatin and Atorvastatin in Vietnamese Patients with Acute Coronary Syndrome: A randomized trial

Tran¹,

Nguyen²,

Tran³

et al. 2021

Pharm Sci Asia

View full text Add to dashboard Cite

show abstract

“…A study like ours also revealed similar results with the use of atorvastatin and rosuvastatin in ACS. Kumar et al concluded better results with the use of rosuvastatin by significantly reducing the hsCRP and ESR [ 5 ].…”

Section: Discussionmentioning

confidence: 99%

“…High-dose statins can accelerate the decrease in hsCRP levels after ACS [ 4 ]. In an open-label randomized trial study of the comparison of atorvastatin and rosuvastatin, it was found that both groups showed statistically significant reduction in serum hsCRP levels (p<0.0001), but rosuvastatin had a more effective role in reducing micro-inflammation in ACS patients [ 5 ]. Furthermore, in a study by Calahorra et al, recurrent atherosclerotic cardiovascular disease (ASCVD) event rates were 2.73 (95% CI: 1.63, 4.25) cases/100 person-years and 2.34 (95% CI: 1.17, 4.10) cases/100 person-years in the atorvastatin and rosuvastatin groups, respectively, which may also be related to reduction in inflammatory markers after first cardiovascular event [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Comparison of Atorvastatin and Rosuvastatin in Reduction of Inflammatory Markers in Acute Coronary Syndrome

Umrani

Jamshed

Rizwan

2020

Cureus

View full text Add to dashboard Cite

Introduction: Patients suffering from acute coronary syndrome (ACS) are found to have elevated levels of inflammatory markers such as high sensitivity C-reactive protein (hsCRP) and erythrocyte sedimentation rate (ESR) in their blood. These elevated inflammatory markers can lead to complications in ACS. Statins such as atorvastatin and rosuvastatin are known to reduce inflammatory markers. Our aim is to compare the efficacy of atorvastatin and rosuvastatin in reducing inflammatory markers. Methods: This prospective, open-label, randomized trial was conducted in the cardiovascular department of tertiary care in a rural area of Pakistan. There were 128 patients diagnosed with ACS who were enrolled in the study. They were randomized into two groups, i.e. group A in which patients received 40 mg rosuvastatin daily and group B in which patients received 20 mg atorvastatin daily. hsCRP and ESR were recorded for all the patients at baseline (before starting therapy) and then again after four weeks. The results were compared between both groups. Result: Out of 128 patients, 113 (88.2%) patients completed the study. According to this study, at the end of four weeks, rosuvastatin reduced hsCRP (p value: < 0.0001) and ESR (p value: 0.015) values significantly more when compared with atorvastatin. Conclusion: In this study, rosuvastatin was significantly superior to atorvastatin in reducing inflammatory markers such as ESR and hsCRP in patients suffering from ACS. Cardiologists should consider using rosuvastatin rather than atorvastatin in management of patients suffering from ACS with elevated inflammatory biomarkers.

show abstract

“…31 No contexto clínico, a atorvastatina reduz processos ateroscleróticos 32 e quadros clínicos de síndrome coronária aguda. 33 De fato, dentre os diversos efeitos pleiotrópicos da atorvastatina, é robusta a sua capacidade vasoprotetora. Ainda assim, não há evidências suficientes que atestam sobre os efeitos e os possíveis mecanismos envolvidos nas ações da atorvastatina, sob a perspectiva do músculo liso vascular e, de forma inédita, sob o PVAT como tecidos inflamatórios em condições de SM.…”

Section: Introductionunclassified

Atorvastatina Atenua o Remodelamento Vascular em Camundongos com Síndrome Metabólica

Carvalho

Ferreira

Barbosa

et al. 2021

Arquivos Brasileiros De Cardiologia

View full text Add to dashboard Cite

Fundamento: A síndrome metabólica é caracterizada por um conjunto de comorbidades. Durante a síndrome, observam-se alterações estruturais no sistema cardiovascular, especialmente o remodelamento vascular. Uma das causas predisponentes para essas alterações é a inflamação crônica oriunda de mudanças na estrutura e composição do tecido adiposo perivascular. Atorvastatina é eficaz no tratamento das dislipidemias. No entanto, seus efeitos pleiotrópicos não são totalmente compreendidos. Supõe-se que, durante a síndrome metabólica, ocorre remodelamento vascular e que o tratamento com atorvastatina pode ser capaz de atenuar tal condição. Objetivos: Avaliar os efeitos do tratamento com atorvastatina sobre o remodelamento vascular em modelo experimental de síndrome metabólica. Métodos: Camundongos Swiss receberam dieta controle ou dieta hiperglicídica por 18 semanas. Após 14 semanas de dieta, os camundongos foram tratados com veículo ou atorvastatina (20mg/kg) durante 4 semanas. Foram avaliados o perfil nutricional e metabólico por testes bioquímicos; análise estrutural da artéria aorta por histologia e dosagem de citocinas por ensaio imunoenzimático. O nível de significância aceitável para os resultados foi p <0,05. Resultados: A dieta hiperglicídica promoveu o desenvolvimento de síndrome metabólica. Tal fato culminou no remodelamento hipertrófico do músculo liso vascular e tecido adiposo perivascular. Além disso, houve aumentos das citocinas TNF-α e IL-6 circulantes e no tecido adiposo perivascular. O tratamento com atorvastatina reduziu significativamente os danos metabólicos, o remodelamento vascular e os níveis de citocinas. Conclusão: Atorvastatina ameniza danos metabólicos associados à síndrome metabólica induzida por dieta hiperglicídica, além de atenuar o remodelamento vascular, sendo esses efeitos associados à redução de citocinas pró-inflamatórias.

show abstract

Comparison of Atorvastatin and Rosuvastatin in Reduction of Inflammatory Biomarkers in Patients with Acute Coronary Syndrome

Cited by 8 publications

References 18 publications

Efficacy of Rosuvastatin and Atorvastatin in Vietnamese Patients with Acute Coronary Syndrome: A randomized trial

Efficacy of Rosuvastatin and Atorvastatin in Vietnamese Patients with Acute Coronary Syndrome: A randomized trial

Comparison of Atorvastatin and Rosuvastatin in Reduction of Inflammatory Markers in Acute Coronary Syndrome

Atorvastatina Atenua o Remodelamento Vascular em Camundongos com Síndrome Metabólica

Contact Info

Product

Resources

About